CSIMarket
 
Protagonist Therapeutics inc   (NASDAQ: PTGX)
 

Protagonist Therapeutics Inc's Customers Performance

PTGX



 
PTGX's Source of Revenues During the corresponding time, Protagonist Therapeutics Inc recorded a revenue increase by 3749.17 % year on year, sequentially revenue grew by 278.72 %. While revenue at the Protagonist Therapeutics Inc 's corporate clients

List of PTGX Customers




for the same period Protagonist Therapeutics Inc recorded revenue increase by 3749.17 % year on year, sequentially revenue grew by 278.72 %.

List of PTGX Customers

Protagonist Therapeutics Inc's Business Units
Fusfertide Clinical Trial Supplies    5.15 % of total Revenue
Single reportable segment    126.4 % of total Revenue






Protagonist Therapeutics Inc's Comment on Sales, Marketing and Customers
















PTGX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Protagonist Therapeutics inc 10,182.41 97.71 -93.16 132
SUBTOTAL 0.00 0.00 0.00 -

Sources: Protagonist Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Protagonist Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Protagonist Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.